COSOPT
Total Payments
$100,000
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $100,000 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $100,000 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Effect of Ophthalmic Preservatives on Trabecular Meshwork Outflow Facility | Merck Sharp & Dohme Corporation | $100,000 | 0 |
Top Doctors Receiving Payments for COSOPT
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $100,000 | 2 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $100,000
Product Information
- Type Drug
- Total Payments $100,000
- Total Doctors 0
- Transactions 2
About COSOPT
COSOPT is a drug associated with $100,000 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2017. In 2017, $100,000 was paid across 2 transactions to 0 doctors.
The most common payment nature for COSOPT is "Unspecified" ($100,000, 100.0% of total).
COSOPT is associated with 1 research study, including "Effect of Ophthalmic Preservatives on Trabecular Meshwork Outflow Facility" ($100,000).